Wealth Enhancement Advisory Services LLC Sells 192 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Wealth Enhancement Advisory Services LLC lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,359 shares of the specialty pharmaceutical company’s stock after selling 192 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Jazz Pharmaceuticals were worth $374,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Jazz Pharmaceuticals by 15.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,476 shares of the specialty pharmaceutical company’s stock valued at $275,000 after purchasing an additional 325 shares in the last quarter. Warther Private Wealth LLC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $3,700,000. Tectonic Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 6.3% during the 3rd quarter. Tectonic Advisors LLC now owns 3,891 shares of the specialty pharmaceutical company’s stock valued at $433,000 after purchasing an additional 232 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 7.2% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 31,562 shares of the specialty pharmaceutical company’s stock valued at $3,516,000 after purchasing an additional 2,115 shares in the last quarter. Finally, International Assets Investment Management LLC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at about $6,703,000. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $123.61 on Friday. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The company has a market cap of $7.63 billion, a PE ratio of 17.41, a price-to-earnings-growth ratio of 1.40 and a beta of 0.57. The business has a 50 day moving average price of $110.64 and a 200-day moving average price of $109.78. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $5.86 EPS for the quarter, beating analysts’ consensus estimates of $4.54 by $1.32. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.04 billion. Jazz Pharmaceuticals had a return on equity of 30.16% and a net margin of 11.60%. Equities analysts anticipate that Jazz Pharmaceuticals plc will post 16.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several research analyst reports. Wells Fargo & Company cut their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Piper Sandler dropped their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Finally, Royal Bank of Canada upped their price target on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $175.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.